Targeted Muscle Reinnervation (TMR) or Regenerative Peripheral Nerve Interface (RPNI) for pain prevention in patients with limb amputation: A systematic review and meta-analysis

Background Phantom limb pain (PLP) and residual limb pain (RLP) after amputation impair rehabilitation, prosthetic use, and quality of life. Targeted Muscle Reinnervation (TMR) and Regenerative Peripheral Nerve Interface (RPNI) give transected nerves a physiologic target and may reduce chronic pain. Objective To synthesize evidence on prophylactic TMR and RPNI at amputation for preventing pain. Methods Following PRISMA 2020 and a published protocol (PROSPERO CRD42024617299), seven databases were searched to 31 July 2026 for studies of prophylactic TMR or RPNI at amputation reporting PLP, RLP, symptomatic neuroma, or safety outcomes. Pain intensity (Hedges' g) and incidence (risk ratios, RR) were pooled separately for PLP and RLP using random-effects DerSimonian-Laird models. Risk of bias (ROBINS-I, RoB 2) and certainty (GRADE) were assessed. Results Twenty-seven studies (30 records, 2,154 participants; 16 comparative) were included. In comparative meta-analyses, TMR/RPNI was associated with lower pain intensity and incidence for PLP (g = -0.68, 95% CI -0.82 to -0.55; RR = 0.56, 0.48–0.65) and RLP (g = -0.68, -0.95 to -0.40; RR = 0.55, 0.42–0.73), or about 300 fewer patients with pain per 1,000 treated. Findings were directionally consistent and stable in sensitivity analyses. No study directly compared TMR with RPNI; indirect subgroup analyses showed no difference. Symptomatic neuroma was less frequent but imprecise (4 studies; RR = 0.35, 0.11–1.09); safety outcomes showed no clear differences. No study had low risk of bias; certainty was low to very low. Conclusions Prophylactic TMR and RPNI were associated with consistently less PLP and RLP than standard nerve management, remaining robust in sensitivity analyses excluding serious-risk-of-bias studies or weaker assumptions. Certainty remains low to very low due to observational designs, risk of bias, heterogeneous outcome definitions, and sparse secondary-outcome reporting. Prospective comparative studies with standardized outcomes are needed to compare techniques.

Authors

Institutions

Publication Details

Journal
medRxiv
Published
2026-11-19
DOI
https://doi.org/10.64898/2026.11.15.26368167
Primary Topic
Pain Management and Treatment
Type
preprint
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
preprint

Targeted Muscle Reinnervation (TMR) or Regenerative Peripheral Nerve Interface (RPNI) for pain prevention in patients with limb amputation: A systematic review and meta-analysis

Javier Pérez de Rojas, Montserrat Royo, Jesús del Moral Preciado, David Gurpegui Gámiz et al.
medRxiv
Pain Management and Treatment
preprint

Targeted Muscle Reinnervation (TMR) or Regenerative Peripheral Nerve Interface (RPNI) for pain prevention in patients with limb amputation: A systematic review and meta-analysis

Javier Pérez de Rojas, Montserrat Royo, Jesús del Moral Preciado, David Gurpegui Gámiz, Bernardo Hontanilla
preprint en

Abstract

Background Phantom limb pain (PLP) and residual limb pain (RLP) after amputation impair rehabilitation, prosthetic use, and quality of life. Targeted Muscle Reinnervation (TMR) and Regenerative Peripheral Nerve Interface (RPNI) give transected nerves a physiologic target and may reduce chronic pain. Objective To synthesize evidence on prophylactic TMR and RPNI at amputation for preventing pain. Methods Following PRISMA 2020 and a published protocol (PROSPERO CRD42024617299), seven databases were searched to 31 July 2026 for studies of prophylactic TMR or RPNI at amputation reporting PLP, RLP, symptomatic neuroma, or safety outcomes. Pain intensity (Hedges' g) and incidence (risk ratios, RR) were pooled separately for PLP and RLP using random-effects DerSimonian-Laird models. Risk of bias (ROBINS-I, RoB 2) and certainty (GRADE) were assessed. Results Twenty-seven studies (30 records, 2,154 participants; 16 comparative) were included. In comparative meta-analyses, TMR/RPNI was associated with lower pain intensity and incidence for PLP (g = -0.68, 95% CI -0.82 to -0.55; RR = 0.56, 0.48–0.65) and RLP (g = -0.68, -0.95 to -0.40; RR = 0.55, 0.42–0.73), or about 300 fewer patients with pain per 1,000 treated. Findings were directionally consistent and stable in sensitivity analyses. No study directly compared TMR with RPNI; indirect subgroup analyses showed no difference. Symptomatic neuroma was less frequent but imprecise (4 studies; RR = 0.35, 0.11–1.09); safety outcomes showed no clear differences. No study had low risk of bias; certainty was low to very low. Conclusions Prophylactic TMR and RPNI were associated with consistently less PLP and RLP than standard nerve management, remaining robust in sensitivity analyses excluding serious-risk-of-bias studies or weaker assumptions. Certainty remains low to very low due to observational designs, risk of bias, heterogeneous outcome definitions, and sparse secondary-outcome reporting. Prospective comparative studies with standardized outcomes are needed to compare techniques.

medRxiv
Clinica Universidad de Navarra (ES), Universidad de Navarra (ES)
Pain Management and Treatment
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon